Cell line · CVCL_1627
Papers93
1 to 20 of 93
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Nuclear localization of the glutaminyl-tRNA synthetase QARS reveals its role in DNA damage response in ovarian cancer. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
Enhanced expression of ADAMTS1 in ovarian carcinomas: loss of ADAMTS1 expression instigates cellular reprogramming of extracellular matrix ensuing altered plasticity, augmented migration and attenuated adhesion. | J Biomed Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Universal principles of cell population growth follow from local contact inhibition. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DYRK1B Inhibition by AZ191 Sensitizes High-Grade Serous Ovarian Cancer to Niraparib Through Promoting Apoptosis and Ferroptosis. | Biomedicines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. | Adv Biol (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The protease ADAMTS5 controls ovarian cancer cell invasion, downstream of Rab25. | FEBS J | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. | NPJ Precis Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial-Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A novel ITGB8 transcript variant sustains ovarian cancer cell survival through genomic instability and altered ploidy on a mutant p53 background. | J Ovarian Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells. | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1627/papers